Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US8940871B2 · kind B2 · utility
38Cited by
259References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2007 |
| Grant date | Jan 27, 2015 |
| Priority date | — |
| Expiry date | Dec 19, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.